Unexpected Benefits in Addiction Treatment from Diabetes Drugs
Research has identified that GLP-1 drugs, primarily used for diabetes, could prevent and alleviate substance use disorders. A study of U.S. military veterans found these drugs reduced risks across various addictive substances. The findings imply a common biological pathway in addictions and suggest broader impacts for addiction medicine.
A groundbreaking study has revealed that GLP-1 drugs, originally designed to treat diabetes, may significantly impact substance use disorders. Conducted primarily on veterans, the research highlights a surprising broad protective effect across various addictive substances, potentially offering a new avenue for addiction medicine.
Dr. Ziyad Al-Aly, who spearheaded the study published in The BMJ, notes the unique potential of these drugs to work across multiple substances, hinting at a common biological pathway that could be targeted for addiction treatment. The research compared the effects of GLP-1 drugs with SGLT-2 inhibitors, revealing notable reductions in substance use disorder occurrences and related health risks.
The study suggests GLP-1 receptors in the brain's mesolimbic system play a role in mitigating cravings, pointing to lasting changes in treating addictions. While Novo Nordisk hasn't initiated addiction-related trials for GLP-1s, increasing independent research and potential clinical application in addiction treatment is encouraging further exploration.
ALSO READ
-
Breakthrough Study: GLP-1 Drugs Reduce Substance Use Disorders in Diabetic Veterans
-
UPDATE 1-More than a third of patients on Wegovy pill are new to GLP-1 drugs, study finds
-
More than a third of patients on Wegovy pill are new to GLP-1 drugs, study finds
-
Novo Nordisk Scores Rare Victory in Battle Against GLP-1 Compounders
-
From Pizza to Protein: How GLP-1s Are Changing America's Eating Habits
Google News